Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.
Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.
Diving Into the Practical Applications of ctDNA in Oncology Care
Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.
Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.
How to Discuss Death: A Conversation of Mortality in Cancer Care
Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.
Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC
Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.